Psyence Biomedical Stock Soars 15.32% on Nasdaq Compliance

Psyence Biomedical's stock surged 15.32% in pre-market trading on June 18, 2025, marking a significant rise in investor interest and confidence in the company's recent developments.

Psyence Biomedical has successfully regained full compliance with Nasdaq's continued listing requirements. This achievement follows a strategic reverse stock split, which was approved by shareholders and implemented to meet Nasdaq's minimum bid price requirement. The company's debt-free balance sheet and strong cash position have been instrumental in this compliance, positioning Psyence Biomedical to accelerate the commercialization of its nature-derived therapeutics.

The company's focus on developing psychedelic-based therapeutics for unmet mental health needs, particularly in palliative care, addiction, and related mental health conditions, has garnered attention. Psyence Biomedical's commitment to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments has been a key driver in its recent success.

Dr. Neil Maresky, Chief Executive Officer of Psyence Biomedical, emphasized the company's dedication to strong corporate governance and long-term value creation for shareholders. The successful compliance with Nasdaq's standards reaffirms the company's strategic direction and its potential for future growth.